Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Goldman Sachs Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Goldman Sachs Group Inc trades at $1,024.12 (market cap $307.69B). The key difference: Goldman Sachs Group Inc is far larger — about 68.5× ACADIA Pharmaceuticals Inc.'s market cap, and Goldman Sachs Group Inc pays a 1.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GS | |
|---|---|---|
Market Cap | $4.49B | $307.69B |
Sector | Health | Financials |
52-Week High | $28.06 | $1.11K |
52-Week Low | $20.06 | $696.57 |
Enterprise Value | $3.69B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Goldman Sachs (GS) trades at $1,055.29, up 3.36% with a bullish technical outlook and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue grew to $58.28B in 2025, and net income margin improved to 29.89%. The company is positioned to benefit from a surge in IPO activity, including leading high-profile deals like Anthropic's upcoming offering.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Key risks include volatile cash flows and high leverage, but robust investment banking pipelines and CEO optimism about market 'greed mode' support growth. Analyst sentiment is mixed but leans positive, with 40% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
